Vital Therapies (VTL) Receives Daily Coverage Optimism Rating of 0.05

Media stories about Vital Therapies (NASDAQ:VTL) have been trending somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Vital Therapies earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.5026130025802 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Shares of VTL traded down $0.50 during midday trading on Friday, reaching $5.95. 245,923 shares of the stock were exchanged, compared to its average volume of 185,556. Vital Therapies has a twelve month low of $2.25 and a twelve month high of $7.30. The stock has a market capitalization of $252.10, a P/E ratio of -4.54 and a beta of 4.26.

How to Become a New Pot Stock Millionaire

Vital Therapies (NASDAQ:VTL) last posted its earnings results on Tuesday, March 13th. The company reported ($0.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.04). During the same period last year, the business posted ($0.37) earnings per share. equities research analysts forecast that Vital Therapies will post -1.35 earnings per share for the current fiscal year.

A number of research firms have recently commented on VTL. Zacks Investment Research cut Vital Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, March 17th. ValuEngine upgraded Vital Therapies from a “strong sell” rating to a “sell” rating in a research report on Wednesday, March 28th. Finally, BidaskClub upgraded Vital Therapies from a “hold” rating to a “buy” rating in a research report on Wednesday.

TRADEMARK VIOLATION WARNING: “Vital Therapies (VTL) Receives Daily Coverage Optimism Rating of 0.05” was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.tickerreport.com/banking-finance/3341102/vital-therapies-vtl-receives-daily-coverage-optimism-rating-of-0-05.html.

About Vital Therapies

Vital Therapies, Inc, a biotherapeutic company, focuses on developing a human hepatic cell-based therapy targeting the treatment of acute forms of liver failure in the United States. Its ELAD system is an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials to allow the patient's own liver to potentially regenerate to a healthy state or to stabilize the patient until transplant.

Insider Buying and Selling by Quarter for Vital Therapies (NASDAQ:VTL)

Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

MaidSafeCoin  Hits One Day Trading Volume of $1.94 Million
MaidSafeCoin Hits One Day Trading Volume of $1.94 Million
$0.48 Earnings Per Share Expected for State Bank Financial  This Quarter
$0.48 Earnings Per Share Expected for State Bank Financial This Quarter
Quantstamp  Hits Market Cap of $102.59 Million
Quantstamp Hits Market Cap of $102.59 Million
Critical Contrast: Generac  and Franklin Electric
Critical Contrast: Generac and Franklin Electric
Head-To-Head Analysis: Avis Budget Group  and Ryder
Head-To-Head Analysis: Avis Budget Group and Ryder
Critical Comparison: GCP Applied Technologies  and Its Competitors
Critical Comparison: GCP Applied Technologies and Its Competitors


Leave a Reply

© 2006-2018 Ticker Report. Google+.